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ABSTRACT: Intracellular protein transduction technology is
opening the door for a promising alternative to gene therapy.
Techniques have to address all critical steps, like efficient cell
uptake, endolysosomal escape, low toxicity, while maintaining
full functional activity of the delivered protein. Here, we
present the use of a chemically precise, structure defined three-
arm cationic oligomer carrier molecule for protein delivery.
This carrier of exact and low molecular weight combines good
cellular uptake with efficient endosomal escape and low
toxicity. The protein cargo is covalently attached by a
bioreversible disulfide linkage. Murine 3T3 fibroblasts could be transduced very efficiently with cargo nlsEGFP, which was
tagged with a nuclear localization signal. We could show subcellular delivery of the nlsEGFP to the nucleus, confirming cytosolic
delivery and expected subsequent subcellular trafficking. Transfection efficiency was concentration-dependent in a directly linear
mode and 20-fold higher in comparison with HIV-TAT-nlsEGFP containing a functional TAT transduction domain.
Furthermore, β-galactosidase as a model enzyme cargo, modified with the carrier oligomer, was transduced into neuroblastoma
cells in enzymatically active form.
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■ INTRODUCTION
Today many different proteins, including recombinant growth
factors and monoclonal antibodies, are used in cancer therapy
and modern medicine.1,2 However, up to date application in
therapy is largely limited to proteins whose site of action is
extracellular at the surface of target cells. Cytosolic delivery of
proteins, due their size and charge, for a long time has been
conceived as impractical. The first observed protein that was
naturally able to translocate through the intact phospholipid
bilayer was the HIV-1 TAT protein.3,4 In the meantime, it has
been discovered that natural homeoproteins such as the
Antennapedia homeobox can cross cell membranes and
internalize into cells as part of their physiological function,5
and numerous homeoprotein-derived natural and artificial
transduction peptides have been identified.6−9 Thus, the
intracellular delivery of active proteins, named protein trans-
duction, now is considered as an interesting option and
alternative to gene therapy, substituting for dysfunctional
cellular proteins.10−12 Protein transduction is expected to be
a safe approach, lacking the introduction of potentially
recombinogenic nucleic acid material.13 In addition, the
technology offers the possibility to transport chemically
modified proteins, containing, for example, artificial or D-
amino acids, considered to be less immunogenic and more
stable toward proteolytic degradation. On the bench side,
intracellular protein delivery technology offers innumerable
possibilities, like localization, interaction, and many other
studies. For in vitro studies, it is possible to use physical
methods, like microinjection or electroporation, to promote an
uptake of the desired protein.14,15 Alternatively, such as for
therapeutic application, a transfection carrier molecule is
needed. The transfection carrier has to prevent the cargo
from extracellular degradation and has to transport it across the
biological barrier of the cell membrane. Once inside the cell,
the carrier−cargo complex has to avoid endolysosomal
degradation either by direct transfer into the cytosol or by
escape from endolysosomal vesicles after endocytosis. After-
ward, the carrier should release its cargo in the cytosol or be
sufficiently inert to warrant full functional activity of the
protein. A perfect carrier system should combine all these entry
functions with low cytotoxicity. In the last decades, many efforts
have been made to create such a perfect carrier system. Aside
from rather exotic technologies, for example, virus-like
particles,16 carbon nanotubes,17,18 and mesoporous silica,19,20
the most common techniques are protein delivery with cationic
lipids,21,22 protein transduction domains (PTDs),11,23−25 and
cationic polymers.26−31 Each of these technologies has got its
limitations such as cell type dependence32 or borders certain
cargo proteins.33 Most commercially available protein trans-
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fection shuttles are based on cationic lipids. A major drawback
of this technology is low stability under serum conditions.34
Protein delivery with cell penetrating peptides, which can be
grouped in two major classes, natural ones like penetratin25,35
or HIV-TAT11 and artificial ones such as oligoarginines,32 is the
best investigated strategy. Protein transduction domains
(PTDs) or cell penetrating peptides (CPPs) as they are also
commonly called are tagged to the cargo protein by genetic
engineering. Especially in cases where the active center of an
enzyme is located near the carboxy- or amino-terminus, this tag
may disturb functionality. The internalization pathway of these
fusion proteins is controversial. Some studies suggest macro-
pinocytosis,36,37 others predict that it is a mixture between
different mechanisms.38−40 The efficiency of the following step,
the retrograde transport out of the endosome is low for most
PTDs41,42 and dependent on cell line and cargo size.32,39
Cationic transfection polymers like polyethylenimine often are
very effective but are lacking of precise structure and often
show high toxicity dependent on the molecular weight of the
used polymer.27−30,43
In this study, we investigate the properties of the three-arm
cationic oligomer 386 as a shuttle for intracellular protein
delivery. This carrier molecule, in contrast to other cationic
polymers used for intracellular delivery, is of precise structure
and low molecular weight. In contrast to structure defined
carriers, purification, analytics, reproducibility, and a clear
structure−activity relationship are problematic steps when
using polymers of distributed molecular weight. Oligomer 386
was recently designed for siRNA delivery.44,45 Protein delivery
places different demands on a carrier than nucleic acid delivery.
While the use as a nucleic acid carrier was based on electrostatic
complex formation, this is not generally feasible for proteins,
which exhibit much lower charge densities, varying from
protein to protein. The transfection oligomer 386 was
covalently bound to cargo proteins (β-galactosidase or
enhanced green fluorescent protein) by a bioreversible disulfide
bond. Covalent coupling of the carrier 386 was indispensable
for forming an effective transduction shuttle. Such disulfide
conjugations have been previously shown to be reversible upon
cytosolic delivery.46,47 Our results reveal that covalent disulfide
coupling of the defined cationic oligomer 386 to a protein leads
to a highly efficient (even in presence of serum) and low toxic
alternative to established protein transfection technologies.
■ EXPERIMENTAL SECTION
General. All chemicals were purchased from Sigma-Aldrich
(Taufkirchen, Germany), unless noted otherwise. SPDP (N-
succinimidyl 3-(2-pyridyldithio) propionate) was synthesized as
described elsewhere.48 β-Galactosidase from E. coli (EC: 232-
864-1) was purchased from Sigma-Aldrich (Taufkirchen,
Germany). Neuro2A neuroblastoma cells (ACC-148) and the
murine fibroblast cell line NIH-3T3 (ACC 59) were purchased
from DSMZ (Braunschweig, Germany).
Cloning, Heterologous Expression, and Purification of
nlsEGFP and HIV-TAT-nlsEGFP. nlsEGFP was prepared
analogously as described previously.49 HIV-TAT-nlsEGFP was
prepared by annealing and cloning the following oligonucleo-
tides encoding for HIV-TAT sequence into the heterologous
expression of the nlsEGFP designed vector.49 Sense:
5′AGCTTGGTTATGGGCGCAAAAAACGCCGTCAGC-
GCCGTCGGGGCC3′. Antisense: 5′TCGAGGCCCCGA-
CGGCGCTGACGGCGTTTTTTGCGCCCATAACCA 3′.
By the common calcium chloride method, this plasmid was
transformed into E. coli BL21(DE3)plysS (Novagen, Merck4-
biosciences, Darmstadt, Germany). Under constant shaking in
TB medium (37 °C), the cells were grown to an optical density
of 0.75 (600 nm). Protein expression was induced with
isopropyl β-D-1-thiogalactopyranoside (Biomol, Hamburg,
Germany) (final concentration 1 mM), and expression was
continued for another 16 h. After ultrasonic cell lysis, the
nlsEGFP was purified by nickel chromatography using a
gradient from binding buffer (50 mM sodium hydrogen
phosphate, 300 mM sodium chloride, and 20 mM imidazole)
to elution buffer (50 mM sodium hydrogen phosphate, 500
mM sodium chloride, and 250 mM imidazole). The protein was
dialyzed overnight at 4 °C against PBS buffer (pH 7.3) using a
dialysis membrane (MWCO 14,000 Da) from Carl Roth
(Karlsruhe, Germany). Finally, the TAT-nlsEGFP was
concentrated with an Amicon Ultra centrifugal filter units
(MWCO 10,000 Da).
Modification of Cargo Proteins with an SPDP Linker
Molecule. Modification of β-Galactosidase. β-Galactosidase
(3 mg, 0.026 μmol) was diluted in PBS buffer (1 mL; pH 7.3, 1
mM EDTA). Then, SPDP (succinimidyl 3-(2-pyridyldithio)-
propionate) was dissolved in DMSO (50 μL; 0.775 μmol) and
added to the above protein solution (30-fold molar excess
compared to β-galactosidase). After incubation (2 h; 20 °C),
the unconjugated linker was removed by size exclusion
chromatography (Sephadex G25 superfine) using PBS buffer
(pH 7.3, 1 mM EDTA) as the mobile phase. The modified
protein was concentrated with Amicon Ultra centrifugal filter
units (MWCO 10,000; Millipore (Billerica, MA)). The protein
concentration was determined at 280 nm using a molar
extinction coefficient of 210000 M−1 cm−1. The ratio of linker
to protein could be calculated, after reducing a sample of the
modified protein with DTT (dithiothreitol) and determination
of the change in absorbance (343 nm; 8080 M−1 cm−1).
Modification of nlsEGFP. nlsEGFP (3 mg, 0.095 μmol) was
diluted in PBS buffer (1 mL; pH 7.3, 1 mM EDTA). Then
SPDP (succinimidyl 3-(2-pyridyldithio)propionate) was dis-
solved in DMSO (50 μL; 1.14 μmol) and added to the above
protein solution. After incubation (2 h; 20 °C), the
unconjugated linker was removed by size exclusion chromatog-
raphy (Sephadex G25 superfine) using PBS buffer (pH 7.3, 1
mM EDTA) as the mobile phase. The modified protein was
concentrated with Amicon Ultra centrifugal filter units
(MWCO 10,000 Da; Millipore (Billerica, MA)). Protein
concentration was quantified by measurement of the
absorbance at a wavelength of 488 nm using an extinction
coefficient of 55000 M−1 cm−1. The ratio of linker to protein
could be calculated, after reducing a sample of the modified
protein with DTT (dithiothreitol) and determination of the
change in absorbance (343 nm; 8080 M−1 cm−1).
Conjugation of Proteins with Transfection Oligomer
386. Transfection oligomer 386 was synthesized as previously
reported.44 SPDP modified proteins (1 mg) were diluted in
Hepps buffer (1 mL, 0.5 M, pH 8.5) and 2-fold molar excess of
oligomer 386 (compared to covalently bound linker), which
was predissolved in water (50 mg/mL), was added for the
modification of nlsEGFP. For the modification of β-
galactosidase, a 5-fold molar excess of oligomer 386 (compared
to covalently bound linker), which was predissolved in water
(50 mg/mL), was used. Thereafter, the pH was adjusted to 7.5
with aqueous HCl (1 M) in both cases. The product was
purified, after 1 h of incubation (20 °C) by Amicon Ultra
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centrifugal filter units (MWCO 10,000 Da; 3× washing steps
with PBS buffer and 1 mM EDTA, pH 7.3).
Cell Culture. 3T3 murine fibroblasts cells were grown in
Dulbecco’s modified Eagle’s medium (DMEM), supplemented
with FCS (10%), glucose (4g/l), stable glutamine (4 mM),
sodium pyruvate (1 mM), penicillin (100 U/mL), and
streptomycin (100 μg/mL). Neuro2A were cultured in
DMEM (1.0g/L glucose) supplemented with FCS (10%),
and 100 U/mL penicillin and streptomycin (100 μg/mL). All
cells were cultured in a 37 °C incubator with 5% CO2 supply
and humidified atmosphere.
Cell Viability Assay. The metabolic activity of transfected
cells was determined by the MTT assay. Neuro2A or 3T3 cells
were seeded in 96-well tissue culture plates (TPP, Transdingen,
Switzerland) at a density of 15000 cells per well, the day before
transfection. Cells were transfected with different concen-
trations of 386-SS-nlsEGFP (0.1; 0.25; 0.5; 0.75; 1.0; 1.5; 2.0;
2.5 μM) in 100 μL of growth media (containing 10% FCS) for
2 h. After washing with PBS and incubating in fresh media (24
h), MTT solution (10 μL per well, 5.0 mg/mL MTT in
phosphate-buffered saline, pH 7.4) was added. The medium
was replaced by 100 μL of DMSO after 3 h. The optical
absorbance was measured at 590 nm, with a reference
wavelength of 630 nm, by a microplate reader (Spectraflour
Plus, Tecan Austria GmbH, Austria). The metabolic activity of
the transduced cells was expressed as relative cell viability,
compared to untreated cells.
β-Galactosidase Transfection. Neuro2A cells were seeded
in 6 well plates (250000 cells per well; one day before
transfection) and transfected with 1 or 2.5 μM 386-β-
galactosidase (in cell culture media containing 10% FCS) for
2 h. For X-Gal staining, a method which was previously
described was used.50 After transfection, cells were washed with
PBS (containing 500 IU heparin per mL and subsequently fixed
with (1.25% (v/v) glutaraldehyde). Following two additional
washing steps with PBS, X-gal staining solution (50 mMTris/
HCl; pH 7.5; 5 mM potassium ferrocyanate, 5 mM potassium
ferricyanate,15 mM sodium chloride, 1 mM magnesium
chloride, 0.1% Triton, and 0.5 mg/mL X-gal) was added and
incubated for 3 h (37 °C). Afterward, the cells were washed
once more with PBS and analyzed with a phase contrast
microscope. For quantitative flow cytometric analysis, C12-
FDG (Invitrogen, Karlsruhe, Germany) substrate was used.
Neuro2A cells (250000) were seeded in 6 well plates the day
before transfection. Transfection was done by pipetting 386-SS-
β-galactosidase into the growth media. After 2 h of incubation,
the cells were washed two times with PBS buffer supplemented
with 500 IU heparin per mL. Afterward, the cells were covered
with fresh growth media containing 2.0 μM C12-FDG. After
incubation for 45 min, the cells were washed again with PBS
and evaluated by flow cytometry.
nlsEGFP Transfection Experiments. For fluorescence
microscopy, 24 h prior to transfection 20000 cells were seeded
in 8 well Nunc chamber slides (Thermo Scientific,
Braunschweig, Germany). Before transfection, the medium
was replaced with fresh medium. Subsequently, the oligomer
modified nlsEGFP was pipetted (final concentration 1 μM)
into cell culture media (10% FCS). After 2 h of incubation, the
cells were washed with PBS buffer (pH 7.3) containing 500 IU
heparin per mL. Afterward, fresh medium was added, and 2 h
later, the cells were examined under the microscope. For FACS
experiments, 24 h prior to transfection 250000 cells were
seeded in 6-well plates. Before transfection, the medium was
replaced with fresh medium containing 10% FCS. Subse-
quently, the oligomer modified nlsEGFP was pipetted into the
cell culture media (usually 0.5 μM, except for the uptake vs
concentration experiment 0.25; 0.5; 0.75; 1.0; 1.5 μM). After
incubation (usually 120 min, except for the uptake vs time
experiment 15; 30; 60; 120; 180 min), cells were washed two
times with PBS buffer (pH 7.3; 500 IU heparin per mL).
Flow Cytometry. 3T3 or Neuro2A cells were seeded in 6-
well plates (250000 cells/well). After transfection and washing
as described above, cells were detached with trypsin/EDTA,
diluted with growth media containing 10% FCS, harvested by
centrifugation, and taken up in phosphate-buffered saline with
10% FCS. Flow cytometry was performed using a Cyan ADP
flow cytometer (Dako, Hamburg, Germany). The cellular
fluorescence was assayed by excitation of nlsEGFP or C12-
FDG at 488 nm and detection of emission at 510 nm. To
discriminate between viable and dead cells as well as for
exclusion of doublets, cells were appropriately gated by
forward/sideward scatter and pulse width, and counterstained
with propidium iodide. Ten thousand gated cells per sample
were collected. Data was recorded with SummitT software
(Summit, Jamesville, NY). Evaluation was done using FlowJo
software (Treestar, Ashland, Oregon, USA).
Endocytosis Inhibition. This experiment was performed as
described elsewhere,31 with minor modifications. Briefly,
250000 cells were seeded in 6 well plates. Before transfection,
the medium was replaced with fresh medium containing 1 mM
amiloride (inhibitor for macropinocytosis), 5 μg/mL chlor-
opromazine (inhibitor for clathrin-mediated endocytosis), or
2.5 mM β-cyclodextrin (inhibitor for caveolae-mediated
endocytosis). After 30 min of incubation, the oligomer
modified nlsEGFP was pipetted into the cell culture media
(0.5 μM). After 120 min, cells were washed two times with PBS
buffer (pH 7.3, 500 IU heparin per mL) and subsequently
analyzed by flow cytometry.
Particle Size and Zeta Potential. Particle size and zeta
potential of the transfection shuttles were measured by dynamic
laser-light scattering using a Zetasizer Nano ZS (Malvern
Instruments, Worcestershire, UK). Modified proteins were
measured in Hepes buffer (20 mM, pH 7.4) at a concentration
of 5 mg/mL. In investigations of the effect of serum on particle
size and zeta potential, 10% FCS was added.
Fluorescence Microscopy and Phase Contrast Micros-
copy. For fluorescence microscopy observation, the nuclei of
the cells were stained by pipetting Hoechst Dye 33342 (1 μg/
mL) into the cell culture media. Ten minutes later, the cells
were observed on an Axiovert 200 fluorescence microscope
from Zeiss (Jena, Germany). A 40× phase 1 objective or a 63×
magnification DIC oil immersion objective (Plan-APOCHRO-
MAT) and appropriate filter sets for analysis of EGFP and
Hoechst fluorescence were used. Data were analyzed and
processed by AxioVision LE software (Zeiss, Jena, Germany).
For phase contrast microscopy, also an Axiovert 200 micro-
scope from Zeiss (Jena, Germany) was used. Pictures were
taken using a 10× magnification phase 1 contrast objective.
Activity Test of Modified β-Galactosidase. The
formation of a fluorescent product (4-methylumbelliferone
(4-MU); λexcitation360 nm, λemission 440 nm) out from the
nonfluorescent 4-methylumbelliferone-β-D-galactopyranoside-
substrate (MUG) by hydrolysis through β-galactosidase51 was
used to determine the relative activity of modified β-
galactosidase, compared to that of the unmodified enzyme.
The assay was performed with minor modification as described
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elsewhere.52 Briefly, the MUG (1 mM, nonlimiting surplus)
substrate was dissolved in PBS buffer (pH 7.4; 5 mM MgCl2).
The reaction was started by the addition of enzyme (0.5 μg/
mL). Enzyme kinetics was monitored by following the
formation of the fluorescent 4-MU product over time on a
Varian Cary Eclipse fluorescence spectrophotometer. As the
substrate was used in nonlimiting surplus, the enzyme activity is
displayed by the slope of the curve.
■ RESULTS AND DISCUSSION
For evaluating intracellular delivery of proteins, we have chosen
two model cargos: β-galactosidase, a big 464-kDa homote-
tramer, where enzymatic activity can be checked histochemi-
cally and by flow cytometry; and a tagged EGFP protein, which
has average protein size (32 kDa) and can be followed in
cellular uptake by flow cytometric methods and in intracellular
distribution by fluorescence microscopy. A nuclear localization
signal (SV40 large T-antigen) tagged EGFP (nlsEGFP) was
selected because only free cytosolic nlsEGFP (and not
endosomal captured nlsEGFP) can translocate into the nucleus;
thus, this feature was utilized to indicate endosomal escape and
natural subcellular behavior.53 An overview of the transfection
concept with disulfide linked 386 is illustrated in Scheme 1.
The covalent attachment of the carrier 386 to the cargo
proteins (β-galactosidase, nlsEGFP) is schematically displayed
in Scheme 2. The biological reversible covalent chemical
conjugation between synthetic molecules or peptides and
proteins via SPDP linker is a well-established method.54 At an
average, 5 linker molecules were introduced per EGFP
molecule. Each β-galactosidase molecule was modified with
an average of 8 linker molecules.
These linker molecules bearing activated thiol groups were
used for the biological reversible covalent attachment of the
cationic transfection oligomer 386.
The formed disulfide bonds should be cleavable by
glutathione in the cytosol after endosomal release, resulting
in a carrier free nlsEGFP or β-galactosidase.46,55 The successful
modification and reversibility of the disulfide bonds are
documented in Supporting Information, Figure S1.
Dynamic light scattering revealed for 386-conjugates
nlsEGFP particle sizes of 26.8 ± 3.6 nm and a zeta potential
of 12.4 ± 0.6 mV. The presence of 10% serum decreased zeta
potential to 5.32 ± 0.1 mV and lead to the formation of
heterogeneous particles with sizes between 32 and 360 nm. For
386-modified β-galactosidase, we obtained particles of 48.3 ±
2.4 nm with a surface charge of 9.5 ± 0.2 mV. In the presence
of 10% FCS, the particle sizes for 386-SS-β-Gal ranged between
51 and 460 nm, and the zeta potential decreased to 4.49 ± 0.5
mV.
Scheme 1. Transfection Concept with Disulfide-linked 386
Scheme 2. Modification of β-Galactosidase (and nlsEGFP)
with Transfection Oligomer 386 over the Biocleavable SPDP
Linker
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To investigate the ability of these transfection shuttles to
penetrate cells and promote endosomal release and natural
subcellular transport, cells were transfected as described in the
Experimental Section. Uptake and subcellular distribution of
nlsEGFP conjugates were pursued using a fluorescence
microscope. Figure 1 (top) nicely demonstrates that all cells
were transfected successfully after an incubation time of 2 h,
using a 0.5 μM concentration of 386-SS-nlsEGFP. The cells
show homogeneous cytoplasmic background fluorescence. This
suggests endosomal escape of the 386-SS-nlsEGFP. In addition,
the protein is concentrated in the nuclei of the cells, confirming
successful escape of the transfection shuttles out of the
endosomes and subsequent active nuclear import facilitated
by the NLS sequence. Cells treated with unmodified nlsEGFP,
as a control, do not show any fluorescence (Figure 1 center).
Cells transfected with 1.5 μM TAT-nlsEGFP also show green
fluorescence all over the cells (Figure 1 bottom), but nuclear
fluorescence is much lower compared to cells transfected with
386-nlsEGFP.
Efficiency of the protein delivery was studied by transfection
of 3T3 cells with different concentrations of 386-modified
nlsEGFP in comparison to a TAT-tagged-nlsEGFP fusion
protein. Evaluation was done via flow cytometry. Cells
transduced with 386-SS-nlsEGFP showed significantly higher
fluorescence intensity, when transfected with the same protein
concentration, compared to cells with PTD-mediated delivery
(Figure 2). The mean cellular fluorescence intensity of 386-SS-
nlsEGFP-treated cells is about 20 times higher than the mean
fluorescence of TAT-nlsEGFP-treated ones. Controls which
were treated with a high concentration (5 μM) of unmodified
nlsEGFP showed only negligible rise in fluorescence.
The same experiment was performed with Neuro2A cells.
Transfection efficiency on Neuro2A cells was lower, compared
to that of the 3T3 cells, when transfected with the same amount
of modified protein. The fluorescent intensity of Neuro2A cells
compared to that of 3T3 cells was around 2-fold lower for cells
transfected with 0.25 μM; at higher concentrations, the mean
fluorescence intensity was around 20% lower (Figure 3A). All
standard transfections were performed in the presence of 10%
fetal bovine serum. To evaluate the influence of serum, a
comparison of transfections with (white bars) or without (gray
bars) serum was made (Figure 3 B). A considerable influence of
Figure 1. Treatment of 3T3 cells with nlsEGFP. Top: carrier 386 was
coupled to nlsEGFP with the SPDP linker. Center: transfection with
unmodified nlsEGFP. Bottom: cells were transfected with TAT-
nlsEGFP. (A) Bright-field picture of the transfected cells, (B) EGFP
fluorescence of the transfected cells, and (C) Hoechst 33342 DNA
stain of the cell nucleus.
Figure 2. Fluorescence assisted cell sorting of 3T3 murine fibroblasts
after transfection with varying concentrations of 386-SS-nlsEGFP in
comparison to TAT-nlsEGFP mediated protein transduction. (I)
Untreated control cells, (II) 5 μM unmodified nlsEGFP, (III) 0.5 μM
TAT-nlsEGFP, (IV) 1.5 μM TAT-nlsEGFP, (V) 0.25 μM 386-SS-
nlsEGFP, (VI) 0.5 μM 386-SS-nlsEGFP, (VII) 0.75 μM 386-SS-
nlsEGFP, and (VIII) 1 μM 386-SS-nlsEGFP.
Figure 3. Average cellular EGFP fluorescence intensity of cells
transfected with 386-SS-nlsEGFP. (A) Comparison of cellular
fluorescence of 3T3 murine fibroblasts (white bars) and Neuro2A
cells (gray bars) after transfection with different concentrations of 386-
SS-nlsEGFP. (B) Influence of serum on transfection efficiency. 3T3
cells treated with 386-SS-nlsEGFP in the presence (white bars) or
absence (gray bars) of 10% FCS.
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serum on transfection efficiency was observed only at
transfection concentrations at 0.5 μM or lower.
We had expected that the amount of internalized material is
concentration dependent, as was already reported for CPP-
assisted transfection studies.40 Nevertheless, we were quite
surprised about the nearly perfect linear relationship between
concentration of protein transfection conjugate and fluores-
cence intensity for both cell types in the tested concentration
area. Similar linear dependency of concentration and uptake
was already reported for internalization mediated by the protein
transduction domain Antp (Antennapedia-homeodomain).38
In the following experiment, we performed a time-course
(Figure 4). Uptake of 386-SS-nlsEGFP increased with
incubation time, resulting in the observed increased fluo-
rescence intensity (Figure 4).
After 15 min of incubation time around 45% and after 30
min incubation already over 90% of the cells were EGFP
positive when transfection was performed with 0.5 μM 386-SS-
nlsEGFP. Such a continuous uptake is supposed to be a strong
hint for endocytosis-mediated uptake.38 Transfection at 4 °C
dramatically lowers internalization of the modified protein
(Figure 5) in 3T3 cells. Cells transfected at 4 °C exhibited only
25% of the fluorescence compared to that of control cells
transfected at 37 °C. This observation indicates that internal-
ization of 386-modified nlsEGFP is an energy-dependent
process and is consistent with most CPPs.31,40,56 To further
analyze the endocytotic pathway in 3T3 cells, we did
transfection experiments in the presence of chlorpromazine
(inhibits clathrin-mediated endocytosis), amiloride (inhibits
macropinocytosis), and β-cyclodextrin (inhibits caveolae-
mediated endocytosis). All these endocytosis inhibitors reduced
transfection efficiency at least a little bit, suggesting that all
three endocytosis pathways participate in internalization.
Clathrin-mediated endocytosis is the predominant internal-
ization route, as chlorpromazine reduced fluorescence to 55%
compared to control cells, transfected under standard
conditions. Caveolae-mediated endocytosis and macropinocy-
tosis seem to contribute, respectively, to around 15−20% of the
uptake. The finding that clathrin-mediated endocytosis may be
the major internalization route is in accordance with the
measured particle size, as particles smaller than 200 nm are
supposed to be taken up mainly through this pathway.57
Aoyama and co-workers found that receptor-mediated
endocytosis is strongly size-dependent with an optimum of
around 25 nm.58−60 This correlates exactly with the measured
size of the transfection shuttles and the observed uptake
pathway.
Flow cytometry experiments using 0.5 μM 386-SS-nlsEGFP
further demonstrate that internalized nlsEGFP disappears after
a few days (Figure 6). This finding was expected as due to cell
proliferation, the intracellular nlsEGFP concentration is dying
out. Another reason might be proteosomal degradation.
Twenty-four hours after transfection, the cells lost approx-
imately one-third of their original mean fluorescence. Within 48
h after transfection, the fluorescence decreased to a fourth and
after 72 h to below 10% of the primordial value.
In addition to transfection of the fluorescent protein
nlsEGFP, transfection of the enzyme β-galactosidase, a big
464 kDa homotetramer, was evaluated. Disulfide conjugation to
386 resulted in considerably reduced enzyme activity (Figure
7A). A possible reason for this finding may be the disturbance
of the tertiary structure of the enzyme due to the charge
inversion of the protein, as unmodified β-Gal is a protein with a
negative isoelectric point (theoretical pI 5.8), and the formation
of rather large protein conjugate particles (48 nm, see above).
Figure 4. Fluorescence assisted cell sorting of 3T3 murine fibroblasts
after transfection with varying transfection time with 0.5 μM 386-SS-
nlsEGFP. (I) Untreated control cells, (II) 15 min incubation, (III) 30
min, (IV) 60 min, (V) 120 min, and (VI) 180 min.
Figure 5. Average cellular fluorescence intensity of 3T3 cells after
transfection with 386-SS-nlsEGFP at 4 °C and in the presence of three
different endocytosis inhibitors: amiloride, β-cyclodextrin, and
chlorpromazine. Fluorescence intensity is normalized to cells trans-
fected at 37 °C.
Figure 6. Average cellular fluorescence intensity of 3T3 cells at
different time points after transfection with 386-SS-nlsEGFP.
Fluorescence intensity is normalized to cells analyzed at 3 h after
transfection.
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Nevertheless, Neuro2A cells transduced with 386-SS-β-Gal are
able to hydrolyze the X-Gal (5-bromo-4-chloro-3-indoxyl-β-D-
galactopyranoside) substrate into β-galactose and the colored
hydroxyindole product61 (Figure 7B). Only cells that were
transduced with 386-SS-β-Gal (but not with unmodified β-Gal)
were stained blue. For a more quantitative analysis, we used
C12-FDG as the substrate, which led to FITC fluorescence
after enzymatic cleavage. Fluorescence was quantified by flow
cytometry, revealing fluorescence of the 386-SS-β-Gal trans-
duced cells but not of cells transduced with unmodified β-Gal
(Figure 7C). Data show that transfection oligomer 386 is able
to transport remarkable amounts of active β-Gal enzyme into
cells, even at the low transfection concentration of 1 μM.
Oligomer 386 was shown to exhibit low cytotoxicity when
used as a carrier for siRNA or pDNA.44 To verify the nontoxic
properties also in case of protein delivery, a cell viability test
was performed. This confirmed this assumption. Figure 8 shows
the low cytotoxicity of the transfection shuttle even at high
concentrations. It exhibited only marginally higher effects on
cell growth and metabolism than unmodified nlsEGFP protein
or TAT-nlsEGFP. With the standard concentration used for the
transfections above (0.5 μM), a decline in metabolic activity of
only 11% in comparison to that of growing untreated cells was
observed (24 h after transfection). Even after transfection with
2.5 μM 386-SS-nlsEGFP, the metabolic cell activity decreased
by only 29%.
■ CONCLUSIONS
We have shown that a sequence-defined cationic transfection
oligomer, with low molecular weight, is applicable to protein
delivery upon covalent disulfide conjugation and enables high
efficient uptake in two different cell lines. Protein transfection
efficiency is linear dependent on cargo−carrier conjugate
concentration as well as on transfection time. Endocytosis
was demonstrated as the main uptake pathway. The carrier
coupling to the cargo protein through a biological reversible
disulfide bond results in natural subcellular behavior after
endosomal release, as demonstrated in nuclear delivery for the
nls-tagged EGFP protein. The chemically precise transfection
shuttle is based on natural and artificial amino acids providing a
pH-responsive positive charge density (medium at extracellular
pH, high at endosomal pH), resulting in efficient transfection
(20 times more efficient than TAT peptide-mediated delivery).
Furthermore, in contrast to polymeric carriers it has low
molecular weight, exhibits no significant toxicity, and, when
delivering an enzyme, was shown to maintain significant
enzyme activity upon the transfection process. This technology
is expected to be applicable to numerous other proteins.
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Figure 7. Transfection of Neuro2A cells with β-galactosidase. (A)
Relative enzymatic activity of β-galactosidase after covalent mod-
ification with the SPDP linker and transfection oligomer 386. (B)
Comparison of Neuro2A cells after treatment with unmodified, natural
β-galactosidase (left) and 386-SS-β-galactosidase (right), washing,
followed by incubation with X-Gal (5-bromo-4-chloro-indolyl-β-D-
galactopyranoside) substrate. (C) Flow cytometry of Neuro2A cells
following transfection with different concentrations of 386-SS-β-
galactosidase, washing, and incubation with C12-FDG substrate.
Unmodified β-Gal was applied as control.
Figure 8. Cell metabolic activity assay (MTT assay) showing the low
cytotoxicity of 386-SS-nlsEGFP, which is comparable to that of
unmodified nlsEGFP. Data shows averages with standard deviations.
Experiments were performed in quadruplicate. Metabolic activity was
normalized to untreated cells (pattern-filled bar in the left). Metabolic
activity of cells 24 h after transfection with unmodified nlsEGFP
(white bars), with 386-SS-nlsEGFP (black bars), or with TAT-
nlsEGFP (gray bars).
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